(ILM1) Medios - Ratings and Ratios

Exchange: XETRA • Country: Germany • Currency: EUR • Type: Common Stock • ISIN: DE000A1MMCC8

ILM1: Cancer, Neurology, Autoimmune, Eye, Infection, Hemophilia Medications

Medios AG, a leading specialty pharmaceutical company based in Berlin, Germany, focuses on the distribution and manufacturing of high-quality medications tailored to specific patient needs. Since its establishment in 2016, the company has grown significantly, expanding its services and reinforcing its market position through strategic initiatives. Medios operates through two core segments: Pharmaceutical Supply and Patient-Specific Therapies. The Pharmaceutical Supply segment specializes in oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia, offering a broad range of critical medications. The Patient-Specific Therapies segment provides customized solutions, including cytostatic infusions, antibody therapies, and parenteral nutrition, catering to individual patient requirements. This segment also supports clinical trials with investigational medicinal products, underscoring Medios commitment to innovation and patient care.

As a key player in the healthcare sector, Medios AG has built a reputation for reliability and precision in the production and delivery of complex pharmaceuticals. The companys state-of-the-art facilities and adherence to stringent regulatory standards ensure the highest quality of its products. Medios AGs strategic focus on niche therapeutic areas and personalized medicine positions it as a valuable partner for healthcare providers and pharmacies across Germany. With a strong foundation in Berlin, the company continues to explore opportunities for growth and expansion in the specialty pharmaceutical market, driven by its mission to improve patient outcomes through innovative and tailored healthcare solutions.

Based on current trends, Medios AGs stock (ILM1) is expected to experience moderate volatility over the next three months. The average volume of 44,436 shares indicates consistent trading activity, while the ATR of 0.38 suggests manageable price fluctuations. The SMA 20 (12.65) and SMA 50 (12.51) are slightly above the last price of 12.26, signaling potential short-term resistance levels. The SMA 200 (14.85) remains above current prices, indicating a bearish trend in the longer term.

From a fundamental perspective, Medios AGs market cap of 339.37M EUR reflects its established presence in the specialty pharmaceutical market. The P/E ratio of 24.42 indicates a premium valuation, while the forward P/E of 8.22 suggests anticipated earnings growth. The P/B ratio of 0.64 points to undervaluation relative to book value, and the P/S ratio of 0.18 highlights the companys low revenue multiple. With an RoE of 2.54, Medios AG demonstrates moderate profitability, which is expected to improve as the company scales its operations and expands its service offerings.

Additional Sources for ILM1 Stock

Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

ILM1 Stock Overview

Market Cap in USD 350m
Sector Healthcare
Industry Medical Distribution
GiC Sub-Industry Health Care Distributors
IPO / Inception

ILM1 Stock Ratings

Growth 5y -64.6%
Fundamental 23.9%
Dividend 0.0%
Rel. Strength Industry -9.25
Analysts -
Fair Price Momentum 10.50 EUR
Fair Price DCF 25.84 EUR

ILM1 Dividends

No Dividends Paid

ILM1 Growth Ratios

Growth Correlation 3m 32.5%
Growth Correlation 12m -60%
Growth Correlation 5y -89%
CAGR 5y -11.33%
CAGR/Max DD 5y -0.16
Sharpe Ratio 12m -1.05
Alpha -34.35
Beta 0.45
Volatility 39.77%
Current Volume 24k
Average Volume 20d 57.2k
What is the price of ILM1 stocks?
As of March 17, 2025, the stock is trading at EUR 12.76 with a total of 24,019 shares traded.
Over the past week, the price has changed by -1.69%, over one month by -6.73%, over three months by +6.87% and over the past year by -8.07%.
Is Medios a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Medios is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 23.89 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ILM1 as of March 2025 is 10.50. This means that ILM1 is currently overvalued and has a potential downside of -17.71%.
Is ILM1 a buy, sell or hold?
Medios has no consensus analysts rating.
What are the forecast for ILM1 stock price target?
According to ValueRays Forecast Model, ILM1 Medios will be worth about 11.6 in March 2026. The stock is currently trading at 12.76. This means that the stock has a potential downside of -9.25%.
Issuer Forecast Upside
Wallstreet Target Price 26.3 105.7%
Analysts Target Price - -
ValueRay Target Price 11.6 -9.2%